The British Journal of Rheumatology, Vol 37, 746-749, Copyright © 1998 by British Society for Rheumatology
FJ Tinahones, MJ Cuadrado, MA Khamashta, F Mujic, JM Gomez-Zumaquero, E Collantes and GR Hughes
Previous studies have shown a cross-reaction between anticardiolipin and
anti-oxidized low-density lipoprotein (LDL) antibodies in patients with the
antiphospholipid syndrome (APS). The aim was to investigate the existence
of a cross-reaction between anti-beta2-glycoprotein-I (beta2-GP-I) and
anti-oxidized LDL antibodies in a group of APS patients. Ninety-three
patients with APS were included in the study; 47 of these patients were
diagnosed as primary APS, while the rest (46 patients) fulfilled criteria
for the classification of systemic lupus erythematosus (SLE). All patients
were positive for the IgG isotype of anticardiolipin antibodies (aCL).
Twelve (26%) SLE-associated APS and 14 (29.7%) primary APS patients had
raised concentrations of IgG antibodies to oxidized LDL. There was no
correlation between anti-beta2- GP-I and anti-oxidized LDL antibodies.
Inhibition experiments showed no cross-reaction either between
anti-beta2-GP-I and anti-oxidized LDL antibodies, or between
anti-beta2-GP-I and anti-native LDL antibodies. Our study suggests that the
presence of both anti-beta2-GP-I and anti- oxidized LDL antibodies in
patients with APS is not due to the structural similarity and consequent
cross-reaction, and that they are two different populations of antibodies
directed against different antigens.
ORIGINAL PAPERS
Lack of cross-reaction between antibodies to beta2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome
Endocrinology Department, Hospital Regional Carlos Haya, Malaga, Spain.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E Matsuura, K Kobayashi, K Inoue, L R Lopez, and Y Shoenfeld Oxidized LDL/{beta}2-glycoprotein I complexes: new aspects in atherosclerosis Lupus, September 1, 2005; 14(9): 736 - 741. [Abstract] [PDF]
|
|
|
|
|
|
E Matsuura, K Kobayashi, T Koike, Y Shoenfeld, M A Khamashta, and G R. Hughes Oxidized low-density lipoprotein as a risk factor of thrombosis in antiphospholipid syndrome Lupus, July 1, 2003; 12(7): 550 - 554. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Kobayashi, M. Kishi, T. Atsumi, M. L. Bertolaccini, H. Makino, N. Sakairi, I. Yamamoto, T. Yasuda, M. A. Khamashta, G. R. V. Hughes, et al. Circulating oxidized LDL forms complexes with {beta}2-glycoprotein I: implication as an atherogenic autoantigen J. Lipid Res., April 1, 2003; 44(4): 716 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Liu, K. Kobayashi, J.-i. Furukawa, J. Inagaki, N. Sakairi, A. Iwado, T. Yasuda, T. Koike, D. R. Voelker, and E. Matsuura {omega}-Carboxyl variants of 7-ketocholesteryl esters are ligands for {beta}2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages J. Lipid Res., September 1, 2002; 43(9): 1486 - 1495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kobayashi, E. Matsuura, Q. Liu, J.-i. Furukawa, K. Kaihara, J. Inagaki, T. Atsumi, N. Sakairi, T. Yasuda, D. R. Voelker, et al. A specific ligand for {beta}2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages J. Lipid Res., May 1, 2001; 42(5): 697 - 709. [Abstract] [Full Text]
|
|
|
|
|
|
G Hayem, P Nicaise-Roland, E Palazzo, M de Bandt, F Tubach, M Weber, and O Meyer Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome Lupus, May 1, 2001; 10(5): 346 - 351. [Abstract] [PDF]
|
|
|
|
 |
|
 A. L. Herrick, K. J. Illingworth, S. Hollis, J. M. Gomez-Zumaquero, and F. J. Tinahones Antibodies against oxidized low-density lipoproteins in systemic sclerosis Rheumatology, April 1, 2001; 40(4): 401 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O Vaarala Antibodies to oxidised LDL Lupus, March 1, 2000; 9(3): 202 - 205. [Abstract] [PDF]
|
|